Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.
Joint Clinical Trials Office

Single-Arm Phase II Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy with Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer

The primary goal of this study is to assess whether using recent advances in technology to treat high intermediate risk and high-risk prostate cancer (HrPCa) can improve clinical outcomes, measured as recurrence-free survival at 2 years after treatment.

Will it cost me anything to be in this study?

No. You will be compensated for your time and effort.

Are there risks or side effects?

Yes. Potential risks and side effects will be discussed with you in detail before you decide to join the study.

Why would Leuprolide help with Alzheimer’s Disease?

Prior research in animals and humans suggests that Leuprolide helps with Alzheimer’s Disease via several mechanisms including regulation of brain cell replication and reduction of inflammation.

What is Leuprolide normally used for?

Leuprolide is approved by the FDA for treatment of prostate cancer in men, endometriosis in women and early puberty in children. It is also commonly used in women preparing for in vitro fertilization. LUCINDA aims to repurpose Leuprolide for Alzheimer's Disease. 

Who can join this study?

This study is open to women over age 60 diagnosed with Mild Cognitive Impairment or Alzheimer’s Disease who are taking a stable dose of a cholinesterase inhibitor such as donepezil (Aricept) Participants must have a study partner (friend, family member or caregiver) who spends at least ten hours per week with them and can participate in all study visits. 

What does the study involve?

If you are interested, a research coordinator will give you detailed information about the study. You will be asked to sign an informed consent form. There will be approximately 8 study visits spread out over 1 year. Study procedures include tests of thinking abilities, blood tests, two MRI scans and one PET scan to measure amyloid in the brain. There will be injection of study drug (Leuprolide or placebo) 4 times over 1 year. 

LUCINDA

Early Identification and Treatment of Occult Metastatic Disease in Stage III Colon Cancer

The purpose of this study is to see if early treatment of your metastatic colorectal cancer and circulating tumor DNA (ctDNA) positivity or negativity, with FOLFIRI, Nivolumab or Encorafenib /Binimetinib/ Cetuximab, helps to prevent stage IV disease. 

Phase I/II Dose-Escalation Study of Fractionated and Multiple Dose 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer

The purpose of the initial (phase I) portion of this study is to find a dose level and administration schedule of the study drug, 225Ac-J591 that can be given without severe side effects. Following selection of the proper dose for each treatment regimen, the purpose of the phase II portion of the study is to test if the regimen of 225Ac-J591 leads to treatment response.